Shares of Alkermes, Inc. closed the week at $14.62 a share. ALKS stock price gained 2.38% during trading on Friday. Alkermes is an integrated biotechnology company.
Alkermes and Cephalon jointly market Vivitrol (formerly Vivitrex) a Naltrexone injection used for the treatment of alcoholism.
Alkermes manufactures a formulation of risperidone for the treatment of schizophrenia and bipolar disorder under the name Risperdal Consta. Risperdal Consta is used by injection every two weeks.
In the pipeline, Alkermes is developing Exenatide as a once weekly treatment for type 2 diabetes.
